Catherine Mezzacappa, MD, MPH
she/her/hers
InstructorAbout
Research
Publications
2025
Pancreatic Ductal Adenocarcinoma After Hepatitis C Infection.
Levinson RN, Bushman R, Tate JP, Skanderson M, Mezzacappa C, Park LS, Brandt CA, Schuster KM, Ketwaroo GA, Yang YX, Justice AC, Wang LL. Pancreatic Ductal Adenocarcinoma After Hepatitis C Infection. JAMA Netw Open 2025, 8: e2543701. PMID: 41236736, DOI: 10.1001/jamanetworkopen.2025.43701.Peer-Reviewed Original ResearchAntibiotic Prophylaxis in Variceal Hemorrhage—Time to Stop?
Mezzacappa C, Garcia-Tsao G. Antibiotic Prophylaxis in Variceal Hemorrhage—Time to Stop? JAMA Internal Medicine 2025, 185 PMID: 40788611, DOI: 10.1001/jamainternmed.2025.3841.Peer-Reviewed Original ResearchPrognostic significance of mild ascites in patients with cirrhosis.
Chong Lugon N, Rabiee A, Mezzacappa C, Kaplan D, Taddei T, Garcia-Tsao G. Prognostic significance of mild ascites in patients with cirrhosis. Hepatology 2025 PMID: 40607762, DOI: 10.1097/hep.0000000000001452.Peer-Reviewed Original ResearchMild ascitesMultivariate Cox proportional hazards analysisMedian follow-up timeGrade 1Associated with poor survivalCox proportional hazards analysisKaplan-Meier methodRetrospective cohort studyDiagnosis of cirrhosisProportional hazards analysisGrade of ascitesHigher hazard of mortalityOvert ascitesGrade 2/3Median survivalHazard of mortalityPrognostic significancePrognostic stageDecompensated cirrhosisImaging ReportingDecompensation eventsPoor survivalCohort studyAscitesCirrhosisSyphilitic Hepatitis: An Atypical Presentation of an Uncommon Disease
Gleason-Vergados J, Cao Y, Chipkin B, Mezzacappa C, Zhang X, Dunne D. Syphilitic Hepatitis: An Atypical Presentation of an Uncommon Disease. Annals Of Internal Medicine Clinical Cases 2025, 4 DOI: 10.7326/aimcc.2024.1364.Peer-Reviewed Original ResearchIdentifying Metabolic Dysfunction-Associated Steatotic Liver Disease Using Natural Language Processing in a US National Cohort.
John B, Bastaich D, Mezzacappa C, Ferreira R, Hentschel A, Samos A, Mahmud N, Taddei T, Kaplan D, Serper M, Dahman B. Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease Using Natural Language Processing in a US National Cohort. The American Journal Of Gastroenterology 2025 PMID: 39950372, PMCID: PMC12264024, DOI: 10.14309/ajg.0000000000003321.Peer-Reviewed Original ResearchElectronic health recordsCardiometabolic risk factorsAlcohol useChart reviewRetrospective study of participantsStudy of participantsLiver diseaseSteatotic liver diseaseIncreased alcohol intakeEligible veteransICD-9/10 codesHealth recordsNational cohortAlcohol intakeEvidence of hepatic steatosisEpidemiological studiesNatural language processing algorithmsRisk factorsStudy cohortOutcome studiesVeteransCohortClinical entityRetrospective studyMetabolic dysfunctionMortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study
Njei B, Mezzacappa C, John B, Serper M, Kaplan D, Taddei T, Mahmud N. Mortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study. Digestive Diseases And Sciences 2025, 70: 802-813. PMID: 39779587, PMCID: PMC11839701, DOI: 10.1007/s10620-024-08764-4.Peer-Reviewed Original ResearchConceptsNon-lean individualsAll-Cause MortalityMajor adverse cardiovascular eventsIncreased risk of all-cause mortalityRisk of all-cause mortalityVeterans Health AdministrationRisk of hepatic decompensationPrevalence of diabetesRisk of cardiovascular mortalityHepatic decompensationHigher mortality riskCardiovascular-related mortalityCox proportional hazards modelsCohort study of patientsCardiovascular outcomesIncident major adverse cardiovascular eventsRetrospective cohort study of patientsProportional hazards modelNon-HispanicRetrospective cohort studyCompeting risk regressionHealth AdministrationMultivariate Cox proportional hazards modelLean individualsAssessed associations
2024
Validation and Epidemiologic Definition of the Novel Steatotic Liver Disease Nomenclature in a National United States Cohort With Cirrhosis
Mezzacappa C, Ochoa-Allemant P, Serper M, Taddei T, John B, Kaplan D, Mahmud N. Validation and Epidemiologic Definition of the Novel Steatotic Liver Disease Nomenclature in a National United States Cohort With Cirrhosis. Clinical Gastroenterology And Hepatology 2024, 23: 1588-1599.e7. PMID: 39689774, PMCID: PMC12167392, DOI: 10.1016/j.cgh.2024.10.035.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseCardiometabolic risk factorsAlcohol use disorderSteatotic liver diseaseLiver diseaseLow high-density lipoproteinChild-Turcotte-Pugh classIncidence rateIncident hepatocellular carcinomaIncreased alcohol intakeAlcohol useClinically relevant definitionAll-Cause MortalityHigher hazard of mortalityNational cohort of veteransUnited States cohortCohort of veteransAcute cardiac eventsHigh-density lipoproteinHazard of mortalityHazardous alcohol useAlcohol intakeCardiac eventsAlcohol exposureHepatocellular carcinomaHepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status
Re V, Newcomb C, Carbonari D, Mezochow A, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Torgersen J. Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status. Pharmacoepidemiology And Drug Safety 2024, 33: e70069. PMID: 39662972, PMCID: PMC11634562, DOI: 10.1002/pds.70069.Peer-Reviewed Original ResearchConceptsProton pump inhibitor initiationHazard ratioVeterans Health AdministrationSevere acute liver injuryProton pump inhibitorsChronic liver diseaseAcute liver injuryRates of hospitalizationSafety of medicationsPPI initiativesHealth AdministrationLiver disease statusMedication exposurePharmacoepidemiological studiesMedicationConfoundingScoresReports of hepatotoxicityDisease statusHepatotoxic medicationsDrug exposurePump inhibitorsHepatotoxic drugsOutpatient initiationHepatic safetyValidation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death
Vutien P, Giustini A, Kim N, Moon A, Hsu C, Mezzacappa C, Borgerding J, Johnson K, VoPham T, Berry K, Beste L, Kaplan D, Taddei T, Ioannou G. Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death. Hepatology 2024, 82: 422-437. PMID: 39689352, PMCID: PMC12266799, DOI: 10.1097/hep.0000000000001183.Peer-Reviewed Original ResearchClinically Significant Portal HypertensionRisk of deathHepatic decompensationLiver stiffnessChronic liver diseasePlatelet countStratify risk of deathLiver diseaseRisk of hepatic decompensationMedian Follow-UpRisk of adverse outcomesSignificant portal hypertensionAssociated with risk of adverse outcomesRisk of decompensationAssociated with riskPortal hypertensionStratify riskFollow-upDecompensationAdverse outcomesCACLDPlatelet measuresPatientsPlateletDeathThe Revised REACH-B Model Predicts Hepatocellular Carcinoma in Patients With Chronic Hepatitis B
Mezzacappa C. The Revised REACH-B Model Predicts Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. Gastroenterology 2024, 169: 173. PMID: 39622300, DOI: 10.1053/j.gastro.2024.11.017.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
News
News
- November 17, 2025
Chronic Hepatitis C Linked to Increased Risk of Pancreatic Cancer, New Study Shows
- September 10, 2024
Liver Cancer Screening Post-Hep C Cure Improves Survival
- September 19, 2023
Liver Center Retreat Highlights Breadth of Liver Research at Yale
- August 01, 2023
Fellow Focus in Four: Catherine Mezzacappa, MD, MPH, Digestive Diseases